Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Want to invest ethically for a brighter future?
(but still make lots of money)?

Want to invest ethically for a brighter future? (but still make lots of money)?

 Take Rask’s FREE Ethical Investing course today.

  • Online & 100% free
  • ETFs, shares & Super
Want to invest ethically for a brighter future? 
(but still make lots of money)?

 Take Rask’s FREE online Ethical Investing course.

S&P/ASX 200 (XJO) daily, here are the ASX shares to watch: WOW, URW, WEB & ANN

The S&P/ASX 200 (ASX: XJO) is set to rise when the market opens this morning.

Westfield URW stock price takes flight – up 43%

The Australian share market or ASX 200 finished 0.7% above open on Tuesday despite trading as much as 2.5% higher during the day on news of Pfizer’s (NYSE: PFE) successful vaccine trials.

For those interested, reports suggest that the treatment has 90% efficacy in protecting from COVID-19 transmission. The process from here is the release of safety data from the trial of over 40,000 patients, the potential emergency approval in late November, and finally worldwide production at best by mid-2021.

Markets and investors clearly liked what they saw, with the announcement triggering a global rally, e-commerce and other similar beneficiaries of the stay-at-home orders were sold off in favour of retail property, energy companies and banks.

In Australia, Unibail-Rodamco-Westfield (ASX: URW) was the leader on the ASX adding 43.5%, yet the share price remains 60% below its pre-COVID highs. This contrast is important given the size of the single-day move and with most assets located in Europe, it is clear the company will remain under pressure for some time.

The Great Rotation

As highlighted, there couldn’t be a more clear rotation out of companies that have benefitted greatly from the COVID-19 pandemic, ranging from glove maker Ansell (ASX: ANN) which fell 9.5%, and Woolworths (ASX: WOW) which was down 4.5% into the most beaten-down sectors.

Oil producers including Oil Search (ASX: OSH), up 16.5%, along with travel exposed companies, including Webjet (ASX: WEB), up 13.5%, may be seeing some light at the end of the tunnel.

Yet, with such a strong recovery, the important question to ask is what are share prices now pricing in? There have been huge rallies, sending many companies close to pre-COVID levels, but will they be able to achieve the same level of revenue and profits they did before?

Only time will tell, but one clear takeaway from today’s events is the growing importance of active management and investment selection evidenced by the ‘index’ return of just 0.7% but huge divergence in the performance of each constituent.

US rally held back by… reality

US markets pared initial gains on Tuesday night, the S&P 500 falling 0.1% and the Nasdaq 100 1.7% as reality set in. Whilst this week’s rally was well behind the largest in 2020 in point terms, the size of individual stock moves was incredible.

Weakness has however crept into markets after the initial bout of optimism after it became clear the long road ahead before a vaccine would actually be produced at sufficient levels along with an unexpected pause in China Sinovac’s Brazilian trial due to a ‘serious adverse event’. One of the biggest impacts of the news was on the US Government Bond rate, which spiked from 0.8% to close to 1%.

This is a positive for the economic recovery, but not those holding what are known as ‘long-duration’ Government bonds. When interest rates increase it reduces the value of existing bonds resulting in capital losses, something not expected from ‘low risk’ assets like these.

Similarly, the gold price fell in USD terms from over US$1,950 to $1,890 as investors moved back to equity markets, burning those invested into ‘gold miners’ as opposed to gold bullion. With inflation still in the outlook and volatility to continue, it still has a role to play, particularly in AUD terms.

1 ASX Stock to Buy RIGHT NOW...

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or enter your email below. We'll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Rask's top analyst has just identified his #1 'MedTech' stock idea for 2021 and beyond. This is a SERIOUS growth stock.

CLICK HERE to get the ASX stock ticker code, 3,500-word analysis and ASX founder interview!

Our expert investment reports are 100% free.

Simply click here or the button below. We'll email you the report.

Disclosure: At the time of publishing, Drew does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: